A recently identified neuropeptide with PRL-releasing capabilities binds to and activates a previously known orphan G protein-coupled receptor, GPR10. We initiated a study to define the pharmacology of the peptide/receptor interaction and to identify the distribution of the peptide and its receptor in the central nervous system to elucidate sites of action of the peptide. The PRL-releasing peptide (PrRP) is a C-terminally amidated, 31-amino acid peptide derived from a 98-amino acid precursor. Radioiodinated PrRP-(1-31) binds to its receptor with high affinity (1 nM) and stimulates calcium mobilization in CHOK1 cells stably transfected with the receptor. A series of Nterminal deletions reveals that the PrRP-(12-31) amino acid is equipotent to PrRP-(1-31). Further N-terminal deletions reduce the affinity of the ligand considerably, although PrRP-(25-31) is still able to compete for binding and behaves as an agonist. The arginine residues at position 26 and 30 are critical for binding, as substitution with either lysine or citrulline reduces the affinity substantially. In situ hybridization reveals a distinct tissue distribution for both the peptide and receptor messenger RNAs. The receptor is expressed abundantly in the reticular thalamic nucleus, periventricular hypothalamus, dorsomedial hypothalamus, nucleus of the solitary tract, area postrema, anterior pituitary, and adrenal medulla. The peptide messenger RNA is expressed in the dorsomedial hypothalamus, nucleus of the solitary tract, ventrolateral reticular nucleus, and intestine. This tissue distribution suggests an alternative function of PrRP than its purported hypophysiotropic function, such as a potential role for PrRP in the central feedback control of neuroendocrine and autonomic homeostasis. Further work using selective agonists and antagonists should help define additional physiological roles of this novel mammalian neuropeptide. (Endocrinology 140: 5736 -5745, 1999) P ROLACTIN IS A multifunctional peptide produced in the pituitary that stimulates mammary tissue development and lactation. PRL secretion is primarily inhibited via dopamine action, but PRL release can also be directly stimulated (1). The exact nature of a PRL-releasing factor had not previously been determined, but TRH and vasoactive intestinal peptide have been implicated in this role (1, 2). Recently, Hinuma et al. isolated a novel peptide that has PRL-releasing properties (3). This elegant study used the increasingly popular method of reverse pharmacology. The researchers were studying an orphan G protein-coupled receptor (the human homolog GPR10 or the rat homolog UHR) that was known to be expressed in hypothalamus and pituitary, and thus rationalized that the ligand must be derived from the hypothalamus. Using traditional biochemical purification and chromatography, they were able to isolate a 31-amino acid peptide that had little or no homology to known peptides. This peptide stimulated arachidonic acid release in cells transfected with the GPR10 receptor and stimulated PRL release from cultured anterior pituitary cells; hence, it was named PRL-releasing peptide (PrRP).
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To determine whether PrRP might have functions other than as a PRL-releasing factor, we initiated experiments to map its distribution in the rat as well as to map the distribution of its receptor. Additionally, we set up an assay to assess the pharmacology of PrRP as a means to identify potential agonist or antagonist peptides that may help identify additional functions of the peptide. Our results confirm the previous findings that the 31-amino acid PrRP binds to and activates the GPR10 receptor. Both peptide and receptor messenger RNA (mRNA) distributions are consistent with this hormonal system playing a role as a PRL-releasing factor. However, there are several novel sites of expression that suggest additional functions for this peptide messenger.
Materials and Methods Cloning
One microgram of polyadenylated mRNA from human thalamus was used to synthesize single stranded complementary DNA (cDNA) using the dT15 primer adaptor [5Ј-GAC TAG TTC TAG ATC GCG AGC GGC CGC CC (T)15-3Ј] from the Superscript Preamplification System for cDNA Synthesis (Life Technologies, Inc., Grand Island, NY). The RNA template was removed from the cDNA:RNA hybrid molecule by digesting with ribonuclease H, the resulting cDNA was directly used in the PCR of the full-length gene. The PCR was performed using Pfu polymerase (Stratagene, La Jolla, CA). The primers 5Ј-AAGCTTGAAT-TCGCCACCATGGCCTCATCGACCACTCGGGGC-3Ј and 5Ј-AAGC-TTTCTAGAACCAAGGCCTGGCTAAGTGGCATCA-3Ј were used for generating a full-length human GPR10 receptor cDNA with included restriction sites for subsequent subcloning into pCi neo vector (Promega Corp., Madison, WI). The PCR product was purified on a column, digested with EcoRI and XbaII, and purified on a low melting point agarose gel. The ligated DNA was transformed into chemically competent DH5␣ cells (Life Technologies, Inc.), and the sequence was con-firmed using the miniprep DNA. The resulting clone was sequenced on an ABI 7700 (PE Applied Biosystems, Foster City, CA).
Cloning of cDNAs for the rat PrRP peptide ligand
A 270-bp cDNA fragment of the rat PrRP mRNA was amplified from rat hypothalamus cDNA using the primers 5Ј-AGTCAGAAGCTTGCT-GCTGCTAAGCTTGGTCCT-3Ј and 5Ј-TCAGTTGGATCCACGCT-GAGAGAACTTGGTG-3Ј. The fragment was digested with HindIII and BamHI, isolated on an agarose gel, and then subcloned into pBluescript-KS ϩ (Stratagene). The rat TRH was cloned from rat brain cDNA by PCR using the primers 5Ј-TCT AGG ATC CAT ATG CCG GGA CCT TGG TTG-3Ј and 5Ј-CAT CAA GCT TCA GAA ATC TGG TAA CCA GGA-3Ј. The Expand High Fidelity PCR System (Roche Molecular Biochemicals, Mannheim, Germany) was used to generate a full-length product with restriction sites for subsequent subcloning into pBluescript (Stratagene). The PCR product was cut with BamHI and HindIII and then ligated overnight at 4 C to the precut vector. The ligated DNA was transformed into chemically competent TOP10FЈ cells (Invitrogen, San Diego, CA), and the sequence was confirmed.
Synthesis of peptides and peptide iodination
The PrRP peptides used in this study were synthesized on an PE Applied Biosystems model 430A peptide synthesizer using the solid phase method with butyloxycarbonyl/benzyl protection and 1-hydroxybenzotriazole/dicyclohexylcarbodiimide activation.
Human PrRP-(1-31) amide was radioiodinated using chloramine-T as previously described (4, 5) . Briefly, 20 g peptide were reacted with 20 g chloramine-T and 2 mCi Na 125 I (New England Nuclear, Boston, MA) for 30 sec at room temperature in 120 l 100 mm phosphate buffer (pH 7.4). The reaction was then quenched by agitation with 100 l 10% (wt/vol) BSA. Reaction products were prepurified using Waters MaxiClean cartridges (Alltech, San Jose, CA) and purified by reversed phase HPLC. The cartridges were wetted with 80% CH 3 CN-0.1% trifluoroacetic acid (TFA), washed with 0.1% TFA (before and after sample application in 0.1% TFA), and eluted with 80% CH 3 CN-0.1% TFA. Eluents from the Maxi-Clean columns were applied to an analytical C 18 column (Vydac, Hesperia, CA) and purified using an acetonitrile gradient with 0.1% TFA used as an ion pair. Baseline separation between cold and radioiodinated peptide was achieved, and the specific activity was estimated to be 2200 Ci/mmol.
Radioligand binding assays
CHO-K1 cells stably transfected with the human PrRP receptor cDNA were grown to confluence in 150-cm 2 dishes. Cells were scraped, pelleted by low speed centrifugation, and frozen at Ϫ80 C for future use. Cell pellets were homogenized in 20 mm Tris-HCl and 0.5 mm EDTA using a tissue grinder (Virtex, high setting, 6 sec). Supernatants from an 800 ϫ g spin were collected and recentrifuged at 30,000 ϫ g for 30 min. Pellets were rehomogenized in binding buffer (120 mm NaCl, 20 mm HEPES, 0.25 mm K 2 PO 4 , 1 mm CaCl 2 , and 1 mm MgSO 4 , pH 7.4). Membranes (ϳ10 g protein) were added to 125 I-labeled PrRP-(1-31) in the presence and absence of unlabeled peptides. Membranes were incubated for 1 h at room temperature and then collected by centrifugation. Supernatant was aspirated, and pellets were washed with 400 l saline and reaspirated. Pellets were then counted for radioactivity in a Packard Cobra II ␥-counter. Nonspecific binding was determined in the presence of 1 m unlabeled PrRP-(1-31). 
Calcium mobilization assays

Autoradiography of [ 125 I]PrRP in rat brain sections
Sprague Dawley rats were anesthetized with a ketamine/xylazine/ acepromazine mix (10:2:1 mg/kg, ip), and the brains were collected and immediately frozen at Ϫ70 C. Coronal 20 m sections were collected onto gelatin-coated slides, dried for 1 h at room temperature under house vacuum, and stored dry at Ϫ80 C. The mounted sections were rehydrated for 45 min in a 0.2 m isotonic neutral phosphate buffer lacking divalent cations (KPBS), incubated 30 min in KPBS and 0.1% BSA, and then incubated 90 -120 min in KPBS, 0.1% BSA, and 66 pm [ 125 I]PrRP with or without 200 nm unlabeled competing peptide. After the binding reaction the cells were washed in iced KPBS and dipped briefly in KPBS-water (1:1). The slides were then dried and exposed to Kodak Biomax autoradiography film (Eastman Kodak Co., Rochester, NY) for 3 weeks.
In situ hybridization
Animals. Adult male Sprague Dawley rats (150 -200 g) were used in all experiments. They were housed two per cage, in a 12-h light, 12-h dark cycle and had free access to food and water. Perfusions were performed in five animals anesthetized with a ketamine/xylazine/acepromazine mix (10:2:1 mg/kg, ip). Brain and peripheral tissues were collected.
Perfusion and histology. Perfusions were performed by anesthetizing the rat and perfusing via the ascending aorta with 50 -100 ml saline, followed by 800-1000 ml 4% paraformaldehyde in 0.1 m borate buffer fixative (pH 9.5 at 10 C), for 20 min. All brain tissue was postfixed overnight in fixative with 10% sucrose. The brains were then frozen in dry ice, and five 1 in 5 series of 30-m thick coronal sections of the whole brain were cut on a sliding microtome. One series of collected brain tissue was stained with thionin for anatomical reference. Peripheral tissue and pituitary were either cut at 15 m on the cryostat or purchased from Novagen (Madison, WI). Peripheral tissue included small and large intestines, dorsal root ganglia, adrenal, testis, heart, pancreas, spleen, liver, and lung.
In situ hybridization. Tissue sections were mounted onto poly-l-lysinecoated slides and fixed an additional 30 min in 10% formalin, digested with proteinase K (10 g/ml in 50 mm Tris-HCl, pH 7.5, and 5 mm EDTA) for 30 min, at 37 C, followed by acetylation (0.25% acetic anhydride in 0.1 m triethanolamine, pH 8.0) and dehydration by alcohol. Each slide received 100 l hybridization mixture containing the [ 35 S]UTPlabeled probe (10 7 cpm/ml). The slides were coverslipped and incubated at 60 C in an oven overnight.
After the incorporation of labeled probe overnight, the tissue was treated with 20 g/ml ribonuclease A for 30 min at 37 C washed for 30 min in 15 mm NaCl-1.5 mm sodium citrate (SSC) at 70 C, dehydrated with ethanol, and exposed to x-ray films for 1-2 days. The slides were then defatted in xylene, rinsed in ethanol, dried, dipped in NBT2 nuclear emulsion (Eastman Kodak Co.; diluted 1:1 with distilled water), and stored in the dark at 4 C. After 12-14 days, slides were developed in D-19 (Eastman Kodak Co.) for 3.5 min at 14 C, rinsed in distilled water, fixed with Polymax T Fixer (Eastman Kodak Co.) for 4 min at 14 C, and washed in distilled water for 1 h.
Arbitrarily, we defined positively labeled cells as any accumulation of silver grains within a cell-sized area that was 5 times above background or control levels.
Complementary RNA (cRNA) probes
Antisense and sense (control) cRNA probes for the PrRP ligand and receptor were generated from the cDNAs. Labeled antisense and sense probes for the ligand were synthesized after linearization with HindIII or BamHI, using T3 or T7, respectively. Labeled antisense and sense cRNA probes for the PrRP receptor were synthesized after linearization with EcoRI or HindIII using T7 or T3, respectively. Labeled antisense and sense cRNA probes for TRH were synthesized after linearization with BamHI or HindIII using T7 or T3, respectively. The cDNA was purified with QIAGEN (Santa Clarita, CA) after the linearization. Probes were labeled with [
35 S]UTP. Unincorporated nucleotides were removed by Sephadex G-50 Quick Spin columns (Roche Molecular Biochemicals). The labeled sense strands served as controls and did not show any specific labeling of cellular localization. All restriction enzymes and RNA polymerases were obtained from Roche Molecular Biochemicals.
Immunohistochemistry and in situ hybridizationcharacterization of PrRP neurons
In situ hybridization revealed a strong expression of PrRP mRNA in the medulla. This localization of PrRP mRNA suggested these may also be catecholaminergic neurons, which are known to project to the endocrine hypothalamus. Avidin-biotin-peroxidase methods were used to confirm whether the expression of the ligand seen within the nucleus of the solitary tract (NTS) and ventrolateral reticular nucleus was catecholaminergic in nature. After a 48-h incubation at 4 C with rabbit antityrosine hydroxylase (TH) affinity-purified polyclonal antibody (1: 200 dilution; Vector Laboratories, Inc., Burlingame, CA), the tissue was exposed for 1 h at room temperature to a goat antirabbit IgG biotinylated affinity-purified antibody at a 1:250 dilution (Vector Laboratories, Inc.). Reaction product was developed with a diaminobenzidene peroxidase substrate kit (Vector Laboratories, Inc.). The nonimmune (blocking) serum that is traditionally used was replaced with 2% BSA and 2% heparin sulfate. Hybridization procedures were similar to the above methods, except for a shortened time in the ethanols, and Nissl counterstain was not applied to tissue sections. The 0.1 ϫ SSC was also replaced with 0.2 ϫ SSC in 50% formamide at 70 C for 30 min. (Fig. 2) . In addition, if either of the arginine positions was substituted with lysine or citrulline, binding affinity was completely lost (data not shown).
PrRP stimulates calcium mobilization in CHOK1 cells transfected with the PrRP receptor
The transfected cells that showed specific [
125 I]PrRP binding were analyzed for receptor function. A previous report demonstrated that PrRP caused increases in arachidonic acid release in PrRP-transfected cells (3) . As this effect can result from a variety of intracellular events, we tested whether PrRP receptor-transfected cells could signal through calcium mobilization. Cells were loaded with fluo-3 fluorescent calcium indicator and then analyzed in real-time for intracellular calcium levels in response to PrRP challenge. PrRP was able to dose dependently increase calcium mobilization (EC 50 , 1 nm; Fig. 3A) . Figure 3B indicates the maximal fluorescent signal obtained with increasing concentrations of PrRP. PrRP-(25-31) was also able to elicit a calcium response, albeit with reduced affinity. All other N-terminally truncated peptides gave calcium responses with EC 50 values comparable to their binding affinities (data not shown). Representative tracings of the actual experiments are shown in Fig. 3A . 
PrRP and its receptor are discretely expressed in different areas of the central nervous system and periphery
The distribution of the mRNAs for both PrRP and its receptor was mapped in whole brain of the rat, and the results are summarized in Table 1 and Fig. 5 . No signal was detected in tissues hybridized to the sense probe (Fig. 6) . The receptor was found to be distributed throughout the brain, particularly the hypothalamus, thalamus, and brain stem. The distribution of the ligand was in more discrete and limited areas of the brain.
Expression of PrRP receptor mRNA and comparison with TRH mRNA
The distribution of the receptor was found in various areas throughout the central nervous system, from forebrain to brain stem. Expression of mRNA for the receptor was high in the reticular nucleus of the thalamus, periventricular hypothalamus (particularly the midportion along the ventricle), area postrema (AP; Fig. 7 ) and NTS; the latter had the strongest signal in the commissural portion. A high level of mRNA expression was also seen in the dorsal portion of the dorsomedial nucleus of the hypothalamus (DMH).
In the forebrain and diencephalon, moderate to low levels of expression of the receptor were seen in layer 2 of the cortex, nucleus accumbens, bed nuclei of the stria terminalis (both medial and dorsolateral divisions), medial preoptic area and nucleus, anteroventral periventricular nucleus, paraventricular nucleus of the hypothalamus (where the strongest levels of signal were in the anterior parvicellular portion), central amygdala, and ventral premamillary nucleus. Signal for the PrRP receptor mRNA in the medial preoptic nucleus was seen in the lateral, medial, and central regions, with the strongest signal seen in the area above the suprachiasmatic nucleus. Expression of the PrRP receptor mRNA was discrete in the midbrain. Low to medium signal was seen in the dorsal raphe nucleus, parabrachial nucleus, and locus coeruleus. As listed above, strong hybridization for PrRP receptor mRNA was expressed in the commissural portion of the NTS; however, moderate levels of hybridization signal were also seen in the caudal portion of the medial and ventrolateral NTS. Low to moderate levels of PrRP receptor expression were seen in the ventrolateral reticular nucleus, intermediate reticular nucleus, and rostral dorsomedial reticular formation/ medial longitudinal fasiculus region. Additionally, the mRNA distributions of TRH (another putative PRL-releasing factor) and PrRP receptor were compared. Both TRH and PrRP receptor were found in the reticular nucleus of the thalamus, medial preoptic nucleus, paraventricular hypothalamus, DMH, and ventromedial medulla (Fig. 5) .
There was moderate hybridization signal for the PrRP receptor in the anterior pituitary. Unexpectedly, the mRNA was not expressed over any particular cell type, but, instead, showed an overall diffuse expression over the entire anterior pituitary, with no expression in the intermediate or posterior pituitary (data not shown). In the periphery, moderate expression of PrRP receptor mRNA was seen in the medulla of the adrenal gland (Fig. 8) . No hybridization signal was detected in other tissues studied.
Expression of PrRP mRNA and colocalization with TH-immunoreactive (TH-ir) cells
Distribution of mRNA for PrRP was more limited than that for the receptor mRNA. In peripheral tissue, expression of mRNA for PrRP was also seen in small and large intestines (Fig. 9) . Signal for PrRP mRNA in the intestine was in the lamina propria, in a population of cells that are perhaps mast cells. In the central nervous system, signal for PrRP mRNA was diffusely distributed in the ventral portions of the DMH, whereas strong hybridization signal was seen in the medial NTS and ventrolateral reticular nucleus. To test whether the positively hybridized cells in these latter two regions were catecholaminergic in nature, in situ hybridization and immunohistochemistry were run concurrently. The PrRP mRNA-labeled cells in the NTS and the ventrolateral reticular nucleus were colocalized with TH-immunoreactive (THir) cells (Fig. 10) . Ninety to 95% of the PrRP mRNA cells in 
Discussion
PrRP is a novel ligand of a former orphan seven-transmembrane domain receptor (GPR10) that has been shown to stimulate the secretion of PRL in vitro. We wanted to characterize the PrRP ligand and receptor by pharmacological amide with an acid resulted in a complete loss of the peptide's ability to compete for binding (data not shown). Modification of any of the C-terminal amino acids (with an alanine) resulted in a reduction in affinity, highlighting the critical structural significance of this region. This is even more important with the arginine residues, as evidenced by the complete loss in affinity when either residue is modified, even with conservative changes. Functionally, unlabeled PrRP was able to elicit calcium mobilization in cells transfected with the PrRP receptor. All truncated peptides showed a reduced potency to stimulate calcium mobilization, but all were agonists. These data suggest that the C-terminal portion of the peptide is the most critical for binding and agonist activity, and that simple deletion of the N-terminal residues will not result in the creation of antagonists as has been shown with other peptide systems. This is consistent with the finding of Fujimoto et al. (6) , who recently isolated a novel 20-amino acid peptide from carp that is highly homologous to PrRP. They showed that N-terminal deletions reduce, but do not eliminate, the agonist activity of the peptide.
The in situ hybridization results demonstrate that PrRP and its receptor are found in discrete areas within the brain and periphery. The mRNA for the ligand is found mainly in the DMH, NTS, ventrolateral reticular nucleus, and intestine. The mRNA for the receptor is more widely distributed throughout the brain, with particularly strong labeling found in the reticular nucleus of the thalamus, periventricular hypothalamus, DMH, AP, and NTS. Autoradiography results from [ 125 I]PrRP binding studies on rat tissue nicely confirm the findings of PrRP receptor mRNA in the reticular nucleus of the thalamus and periventricular hypothalamus. Binding was not found in any other brain region, but the autoradiography technique may not have been sensitive enough to detect binding in the other regions that may have had a lower signal. The in situ hybridization results from our study are similar to those of an immunocytochemical study that has just been published (7) . This study looked at the distribution of PrRP in rat brain using two monoclonal antibodies, one antibody that recognizes the C-terminal and another that recognizes the internal sequence of PrRP. Immunoreactive cell bodies were found mainly in the DMH and NTS, whereas dense immunoreactive nerve fibers were found in the PVN, supraoptic nucleus, paratenial thalamic nucleus, basolateral amygdaloid nucleus, and bed nuclei stria terminalis. These immunoreactive nerve fiber networks are in close proximity to areas in which the PrRP receptor mRNA is distributed. It is likely that the ligand is produced in the DMH, NTS, and ventrolateral medulla and is transported to other sites to be released.
PrRP: relevant roles; A1 and A2 cell groups
PrRP is a recently characterized peptide that has been shown to promote PRL secretion in cultured cells (3); however, the mRNA distribution we have described in this paper suggests that PrRP has functions in addition to that of a PRL-releasing peptide. These findings are supported by the results reported by Samson et al. (8) . They found that PRLreleasing activities of two forms of PrRP (PrRP-20 and PrRP-31) were comparable with that of TRH in dispersed rat anterior pituitary cell cultures. The PrRP-21 and PrRP-30 did not significantly alter PRL secretion in male anterior pituitary cells, and only the highest doses tested significantly stimulated PRL secretion in female pituitary cells. Using similar doses of the two forms of PrRP and of TRH, it was found that the magnitude of response was much greater and quicker with TRH. This suggests that although PrRP and its receptor may be acting to release PRL in some tissues, it may have some independent functions of its own. The localization of the PrRP and receptor mRNA in the rat brain and peripheral organs strongly suggest that this function may involve circuitry in controlling neuroendocrine and autonomic homeostasis; specifically, they may have roles in cardiovascular regulation and acting in response to various stressors. For example, a high level of the PrRP receptor mRNA is found in the area postrema. The AP is the most caudal circumventricular organ, located on the dorsal surface of the medulla, and it lacks a blood-brain barrier. The AP has been shown to be involved in cardiovascular and autonomic control, such as functioning as an emetic chemoreceptor trigger zone and in food ingestion. The AP projects to structures such as the NTS, dorsal motor nucleus of the vagus, and the region of the ventrolateral medullary catecholaminergic column. The major central afferents to the AP include neurons in the paraventricular and dorsomedial hypothalamic nuclei. The AP also receives vagal afferent inputs (9) . Furthermore, PrRP mRNA and TH-ir cells are colocalized within the A1 cell group in the ventrolateral reticular nucleus and with the A2 cell group in the NTS, findings that have been verified in a study by Chen et al. (10) . Medullary catecholaminergic neurons have been implicated in mediating autonomic and neuroendocrine responses. The medullary catecholamine neurons are activated by various stress models and have strong connections with the neuroendocrine hypothalamus. This has been shown in response to cardiovascular challenges, namely those that affect blood pressure and volume (11) and in sending visceral sensory information to forebrain structures (12) .
DMH
The DMH is another nucleus that has a role in both autonomic and neuroendocrine homeostasis. The mRNA for both the PrRP and receptor are found in the DMH, with high levels of the receptor found in this region. The DMH is involved in sympathetic nervous system outflow to the adrenal gland, is part of a circuitry regulating cardiovascular responses to stress, and seems to be involved in feeding mechanisms (13) . To what extent PrRP may play a role in hypothalamic regulation of hormone secretion and food intake has yet to be determined.
PrRP receptor mRNA: distribution in pituitary
PrRP receptor mRNA has previously been shown to be expressed in both human and rat pituitary (3, 14) . This expression is undoubtedly linked to its capability to modulate PRL release. Our results indicate that PrRP receptor mRNA was diffusely expressed over the entire anterior pituitary and was not localized to any specific cell group, even at the cellular level. This diffuse expression of PrRP receptor in the pituitary coupled with the lack of PrRP ligand mRNA in the median eminence again brings into question the view that PrRP is a true PRL-releasing factor.
PrRP and receptor in peripheral nervous system
Of the numerous peripheral tissues we tested, only two tissues showed expression of PrRP and its receptor mRNA. The expression of PrRP receptor mRNA (this study) and immunoreactive PrRP (15) has been found in adrenal gland. We found the expression of PrRP receptor (but not that of PrRP) mRNA to be localized to the adrenal medulla. The adrenal medulla secretes noradrenalin and adrenalin in times of stress, thereby stimulating the nervous system and exerting various metabolic effects on the body. Further studies will need to be performed to determine whether PrRP or its receptor may have a function in the adrenal, perhaps by mediating autonomic responses to stressful situations.
Expression of PrRP mRNA was found in a distinct cell population in the lamina propria in small and large intestines. It appears that these labeled cells are mast cells, but further studies will need to be performed to definitively answer this question. Evidence suggests that the central nervous system directly communicates with the mast cells in the gastrointestinal mucosa (16) and that this may be related to stress-related gut dysfunction (17) .
PrRP and TRH
Of interest is the fact that TRH and the PrRP receptor have a very similar mRNA distribution. In addition to the expression of TRH mRNA in the reticular nucleus of the thalamus, TRH mRNA is found in the medial preoptic nucleus, paraventricular hypothalamus, DMH, and ventromedial medulla. No hybridization is found in the median eminence (this study) (18) . Although TRH is thought to be a PRLreleasing factor and is involved in the regulation of TSH secretion from the anterior pituitary gland, it has been shown to exert central effects independent of anterior pituitary regulation. This includes thermoregulation, modulation of the autonomic nervous system outflow, and stimulation of gastric acid secretion via the dorsal vagus nerve (19 -21) . The similarities in the mRNA distribution of TRH and the PrRP receptor and the evidence that in some of these brain regions TRH has functions outside of anterior pituitary regulation lend support to the hypothesis that PrRP may also have multiple functions in the central nervous system. Finally, although PrRP and TRH are thought to be PRL-releasing factors, PrRP has been shown to be a weak PRL-releasing factor compared with TRH, suggesting that a PRL-releasing factor may not be the primary function of PrRP and its receptor.
Conclusion
The present study demonstrates that PrRP is expressed in a few discrete areas of brain: the DMH, NTS, and ventrolateral and intermediate reticular nucleus. The PrRP receptor is more widely expressed in the brain, with medium to strong expression in the reticular thalamus, medial preoptic area, various hypothalamic regions, locus coeruleus, AP, and NTS. The pattern of expression suggests that this ligand and receptor are part of a neuronal circuitry involved in controlling neuroendocrine and autonomic homeostasis. Furthermore, the colocalization of PrRP with medullary catecholaminecontaining neurons suggests that this circuitry may involve activation of endocrine hypothalamic groups in stressful situations. Further research needs to be performed to elucidate the function of PrRP and its receptor in the central and peripheral nervous systems.
